Arizona Clinical Research Center | Tucson, AZ

Research site
1825 N Kolb Road, Tucson, Arizona, United States of America
Site insights

Top conditions

Lung Cancer (11 trials)

Non-Small-Cell Lung Carcinoma (10 trials)

Colorectal Cancer (9 trials)

Pancreatic Cancer (8 trials)

Lymphoma (7 trials)

Top treatments


Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


7 of 70
Status: Active
Trial type: Interventional
Funder type: Industry

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in particip...

Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Drug: Tiragolumab
Drug: Durvalumab

The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate ca...

Active, not recruiting
Prostate Cancer
Biological: Nivolumab
Other: Placebo

The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or...

Not yet enrolling
Multiple Myeloma
Drug: Dexamethasone
Drug: Elotuzumab

This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), p...

Active, not recruiting
Non Small Cell Lung Cancer Metastatic
Sensitizing EGFR Gene Mutation
Drug: Zimberelimab
Drug: Etrumadenant

This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in partic...

Active, not recruiting
Metastatic Colorectal Cancer
Drug: Bevacizumab
Drug: Zimberelimab

The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol inv...

Active, not recruiting
Multiple Myeloma
Drug: Pomalidomide
Drug: Elotuzumab

MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology...

Active, not recruiting
Breast Cancer
Renal Cell Carcinoma
Drug: nab-paclitaxel
Drug: Bevacizumab

Trial sponsors

CTI BioPharma logo

CTI BioPharma (7 trials)

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems